Adalimumab biosimilar - TR-Pharm
Latest Information Update: 21 May 2024
At a glance
- Originator TRPHARM
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rheumatoid arthritis
Most Recent Events
- 29 Apr 2024 Phase-III clinical trials in Rheumatoid arthritis (Parenteral), prior to April 2024 (TRPHARM pipeline, April 2024)